uri
viral
origin
et
al
orthomyxovirus
influenza
b
paramyxovirus
parainfluenza
respiratori
syncyti
virus
coronavirus
adenovirus
enterovirus
coxsacki
echo
virus
caus
common
cold
howev
cold
caus
type
rhinovirus
musher
cooper
et
al
strain
adenovirus
caus
pharyng
resembl
strep
throat
rhinovirus
unrespons
antibiot
medic
control
bacteri
infect
antibiot
treatment
adenoviru
infect
valu
sometim
even
harm
supress
normal
bacteri
flora
enabl
resist
opportunist
pathogen
grow
uncontrol
way
nester
et
al
differ
bacteria
includ
chlamydia
pneumonia
mycoplasma
pneumonia
sreptococcu
pneumonia
bordetella
pertussi
haemophilu
influenza
staphylococcu
aureu
involv
upper
respiratori
system
murray
et
al
common
uri
bacteri
origin
pharyng
caus
group
betahemolyt
streptococci
streptococc
pyogen
main
repres
account
pharyngitid
pool
portug
streptococcu
pneumonia
haemophilu
influenza
import
bacteri
pathogen
otiti
media
bacteri
conjunct
less
commonli
mycoplasma
pneumonia
streptococc
pyogen
staphylococcu
aureu
caus
agent
otiti
media
studi
carri
czech
republ
differ
citi
among
healthi
children
age
year
show
overal
carriag
pathogen
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
staphylococcu
aureu
preval
zemlickova
et
al
diagnosi
uri
base
review
symptom
physic
examin
laboratori
test
direct
identif
bacteri
pathogen
base
routin
laboratori
test
includ
grow
bacteria
cultur
detect
bacteri
metabol
activ
singl
enzym
test
catalas
oxidas
ureas
coagulas
test
molecular
method
balentin
siamak
harvey
et
al
complement
fixat
test
direct
agglutin
techniqu
latex
agglutin
enzym
link
immunosorb
assay
elisa
tradit
serolog
method
use
detect
antibodi
patient
serum
tradit
diagnost
method
viral
pathogen
includ
growth
viru
cell
cultur
observ
viru
particl
electron
microscopi
detect
viral
nucleic
acid
virusspecif
antibodi
blood
meneghetti
filmarray
panel
multiplex
nucleic
acid
test
intend
simultan
qualit
detect
identif
multipl
respiratori
pathogen
nucleic
acid
nasopharyng
swab
new
platform
combin
autom
sampl
prepar
nucleic
acid
extract
polymeras
chain
reaction
pcr
base
detect
singl
unprocess
sampl
h
biofir
diagnost
salt
lake
citi
ut
method
allow
identif
differ
respiratori
pathogen
nasopharyng
swab
viral
etiolog
three
bacteri
origin
idaho
technolog
present
studi
seek
determin
individu
advantag
disadvantag
differ
diagnost
tool
pathogen
underli
uri
well
circumst
specif
method
would
advantag
anoth
one
studi
approv
ethic
commite
jesseniu
faculti
medicin
martin
slovakia
result
respiratori
panel
elisa
test
perform
depart
clinic
microbiolog
martin
univers
hospit
evalu
compar
function
advantag
disadvantag
method
focus
total
number
filmarray
panel
test
number
posit
result
spectrum
pathogen
detect
connect
clinic
diagnosi
nasopharyng
swab
examin
use
respiratori
panel
develop
idaho
technolog
biofir
diagnost
salt
lake
citi
ut
presenc
pathogen
adenoviru
bocaviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
respiratori
syncyti
viru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
assess
diagnost
efficaci
new
method
venou
blood
sampl
draw
two
patient
concurr
examin
laboratori
presenc
eight
pathogen
adenoviru
influenza
influenza
b
parainfluenza
viru
respiratori
syncyti
viru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
test
hitherto
commonli
use
elisa
method
addit
hemagglutin
inhibit
test
influenza
b
perform
patient
depart
virolog
region
institut
public
health
banska
bystrica
slovakia
filmarray
panel
perform
time
identifi
uri
pathogen
hospit
patient
acut
respiratori
infect
januari
posit
result
obtain
sampl
four
sampl
turn
posit
human
rhinovirusenteroviru
detect
pathogen
parainfluenza
viru
human
metapneumoviru
coronaviru
influenza
b
adenoviru
two
differ
pathogen
identifi
one
patient
human
rhinovirusenteroviru
adenoviru
posit
result
laboratori
test
summar
tabl
result
correspond
number
respiratori
infect
diagnos
hand
uri
pneumonia
acut
inflamm
nasopharynx
acut
bronchiti
hypothermia
unrel
extern
temperatur
undefin
fever
comparison
specimen
obtain
two
patient
test
simultan
tradit
elisa
filmarray
panel
method
venou
blood
sampl
nasopharyng
swab
taken
patient
either
method
respect
one
patient
result
neg
etiolog
agent
could
identi
elisa
method
total
day
requir
obtain
full
panel
result
tabl
patient
addit
cultur
specimen
obtain
nasopharyng
swab
patient
also
neg
pathogen
howev
nasal
swab
specimen
examin
filmarray
panel
yield
posit
result
human
rhinoviru
human
enteroviru
tabl
patient
neg
elisa
elisa
perform
second
patient
show
elev
igg
parainfluenza
viru
igg
posit
cut
index
result
howev
inconclus
regard
acut
current
infect
rather
confirm
previou
encount
viru
result
regard
influenza
infect
also
neg
igm
cut
index
igg
cut
index
test
time
eight
pathogen
amount
day
tabl
patient
examin
filmarray
panel
patient
identifi
etiolog
agent
influenza
tabl
patient
identif
confirm
serum
hemagglutin
inhibit
test
hit
done
depart
virolog
region
institut
public
health
bystrica
slovakia
hit
perform
twice
week
apart
assess
possibl
chang
antibodi
titer
first
sampl
influenza
b
titer
neg
signific
rise
antibodi
titer
influenza
second
sampl
hit
assess
took
day
result
shown
tabl
health
insur
gave
point
test
make
total
point
plu
point
sampl
cultur
upper
respiratori
tract
point
cultur
form
lower
respiratori
tract
insur
point
valu
laboratori
therefor
receiv
run
elisa
addit
cultur
sum
total
real
materi
cost
hand
health
insur
gave
point
pathogen
target
filmarray
panel
make
total
point
come
real
materi
cost
amount
per
sampl
insur
reimburs
influenza
b
test
type
influenza
test
twice
give
cost
total
actual
laboratori
cost
hit
test
time
less
insur
reimburs
laboratori
test
gener
recommend
evalu
upper
respiratori
infect
test
specif
pathogen
help
therapi
depend
result
target
therapi
avail
virus
caus
uri
therefor
viral
test
rare
indic
uncompl
uri
outpati
set
howev
confirm
viral
condit
influenza
may
reduc
inappropri
use
antibiot
balentin
siamak
consid
benfit
patient
speed
identifi
etiolog
agent
clearli
favor
filmarray
system
method
readili
identifi
etiolog
agent
patient
appli
present
studi
wherea
hit
identifi
viru
repeat
sampl
second
patient
howev
identif
etiolog
agent
benefit
first
patient
mild
symptomatolog
coryza
target
treatment
human
rhinovirusenteroviru
infect
need
symptomatolog
second
patient
sever
speed
pathogen
identif
crucial
commenc
appropri
treatment
especi
suspect
case
influenza
earli
administr
neuraminidas
inhibitor
significantli
reduc
mortal
rate
case
accuratelli
target
therapi
enorm
benefit
patient
laboratori
cost
run
one
examin
differ
method
show
filmarray
multiplex
pcr
respiratori
panel
expens
elisa
hit
cultiv
one
examin
filmarray
panel
brought
per
patient
profit
laboratori
wherea
profit
run
elisa
togeth
cultiv
hit
per
patient
therefor
filmarray
respiratori
panel
best
term
profit
margin
laboratori
least
favor
health
insur
serolog
diagnost
method
elisa
hit
identifi
patholog
agent
host
immun
system
elicit
respons
howev
advantag
method
readili
avail
mani
laboratori
least
pricey
health
insur
disadvantag
spectrum
pathogen
detect
small
clinic
benefit
filmarray
respiratori
panel
quick
exact
may
identifi
broader
spectrum
possibl
pathogen
sinc
uri
viral
origin
treatment
avail
diagnosi
provid
filmarray
panel
alway
necessari
method
use
individu
basi
clinic
justifi
econom
standpoint
filmarray
respiratori
panel
profit
laboratori
critic
ill
patient
spectrum
diagnost
method
use
obtain
diagnosi
fast
possibl
patient
minor
respiratori
tract
infect
ration
approach
undertaken
sinc
speed
accuraci
diagnosi
less
crucial
decis
choos
specif
diagnost
method
rest
medic
caregiv
staff
